Chairman: “Jeremy, welcome to the Board. What attracted you to join Phylogica?” Mr Curnock Cook: “I was particularly attracted to the opportunity to develop Phylogica’s strategy, because it is not often that one has the opportunity to help grow a company, which controls global access to a new source of proprietary therapeutics. This is an important period of transition for the Company since it is only two years into the commercialisation phase and as it continues to validate its technology, both scientifically and through accumulating Pharma alliances. I believe that if Phylogica continues on its current trajectory, the Company will prove an attractive acquisition target for the pharmaceutical industry.”
I like this industry veteran and new board member's confidence in PYC's phylomer library and associated technology's potential takeover value. One other similar company (Domantis, 2007) had been bought lock stock and two smoking barrels for many multiples of Market Capitalisation, despite no clinical candidates.
PYC has fairly proved itself a credible value package and I wouldnt be surprised about a purchase offer even before more major collaborations have been nailed down.
DYOR and go PYC
PYC Price at posting:
4.0¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)